Stephanie Halene MD

Hematology•New Haven, CT

Professor, Hematology, Comprehensive Cancer Center, Yale University School of Medicine

Join to View Full Profile

Park St.New Haven, CT 06520
Phone+1 203-200-4363

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2006
Eberhard Karls University Faculty of MedicineClass of 1993

Certifications & Licensure

CT State Medical License 2006 - 2026
American Board of Internal Medicine Hematology

Publications & Presentations

PubMed

An in vivo screen identifies NAT10 as a master regulator of brain metastasis.
Jocelyn F Chen, Peng Xu, Wesley L Cai, Huacui Chen, Emily Wingrove
Science Advances. 2025-03-28
1 citations
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang
Blood. 2025-03-27
In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients.
Philip C Mack, James M Crawford, Andres Chang, Anna Yin, Sabra L Klein
Journal of the National Cancer Institute. 2025-03-24

Journal Articles

SRSF2 Mutations Drive Oncogenesis by Activating a Global Program of Aberrant Alternative Splicing in Hematopoietic Cells
Radovan Vasic, Stephanie Halene, Nature

Abstracts/Posters

Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrg Mice
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The GPR68/BCL2 Axis Remodels Metabolism in AML By Relocating Calcium
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Rel...
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Mye...
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure
Stephanie Halene, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Proton Sensor GPR68 Is Essential to Maintain Myeloid Malignancies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Listen to, "How Can Artificial Intelligence Advance Medical Education and Research to Transform Patient Care?"June 11th, 2024
New Yale Study Shows Potential Target for Treating Blood CancersMarch 31st, 2022
Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid OrgansOctober 20th, 2021
Join now to see all

Grant Support

Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)YALE UNIVERSITY2024–2029
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)YALE UNIVERSITY2024–2029
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)YALE UNIVERSITY2024–2029
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)YALE UNIVERSITY2024–2029
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)YALE UNIVERSITY2024–2029
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)YALE UNIVERSITY2024–2029
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)YALE UNIVERSITY2024–2029
Center for Human Lymphoma Spatiotemporal Atlas (HuLymSTA)YALE UNIVERSITY2024–2029
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AMLYALE UNIVERSITY2022–2027
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AMLYALE UNIVERSITY2022–2027
Targeting Defective DNA Damage Response Pathways in IDH1/2-mutant AMLYALE UNIVERSITY2022–2027
Yale TMC for Cellular Senescence in Lymphoid OrgansYALE UNIVERSITY2021–2026
Yale TMC for Cellular Senescence in Lymphoid OrgansYALE UNIVERSITY2021–2026
Yale TMC for Cellular Senescence in Lymphoid OrgansYALE UNIVERSITY2021–2026
Yale TMC for Cellular Senescence in Lymphoid OrgansYALE UNIVERSITY2021–2026
Yale TMC for Cellular Senescence in Lymphoid OrgansYALE UNIVERSITY2021–2026
Yale TMC for Cellular Senescence in Lymphoid OrgansYALE UNIVERSITY2021–2026
Yale TMC for Cellular Senescence in Lymphoid OrgansYALE UNIVERSITY2021–2026
Yale TMC for Cellular Senescence in Lymphoid OrgansYALE UNIVERSITY2021–2026
Modeling myelodysplasiaCINCINNATI CHILDRENS HOSP MED CTR2021–2025
Modeling myelodysplasiaCINCINNATI CHILDRENS HOSP MED CTR2021–2025
The role of m6A RNA modification as modulator of dsRNA induced cell-intrinsic innate immune responses in hematopoiesisYALE UNIVERSITY2021–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic MalignanciesYALE UNIVERSITY2020–2025
Mechanisms of Leukemogenesis in AMKLYALE UNIVERSITY2020–2025
Role Of C/Ebpepsilon In Myeloid DifferentiationNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2010

Stephanie Halene MD

Dr. Halene is on Doximity

Education & Training

Certifications & Licensure

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.